Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ATHENA’s First Launch in Russia with Levocetirizine ODT
Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.
Product Name : Levocetirizine-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions
Details : Levocetirizine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2012
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions
Details : Levocetirizine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2012
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation
Details : Xyzal (Levocetirizine Dihydrochloride) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Xyzal
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2018
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Zensei Pharmaceutical Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2018
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Zensei Pharmaceutical Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of Levocetirizine
Details : Levocetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2015
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Study of Levocetirizine Oral Solution
Details : Levocetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2012
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition
Details : Levocetirizine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Feeding and Eating Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2012
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics
Details : Levocetirizine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2012
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
